Anteris Technologies (AVR) Share Scheme Meeting summary
Event summary combining transcript, slides, and related documents.
Share Scheme Meeting summary
9 Jul, 2026Opening remarks and agenda
Meeting convened to consider a scheme of arrangement for redomiciling to the US via acquisition by ATGC.
Chairperson John Seaberg officiated, with directors and legal advisors present both in person and online.
Quorum confirmed and meeting formally opened, with participation available both virtually and in person.
Corporate governance
Meeting held under Supreme Court of Queensland order, with procedures outlined for voting and questions.
Voting conducted by poll, with Computershare appointed as returning officer.
Shareholders, proxies, and representatives could vote and ask questions online or in person.
Strategic initiatives and plans
Proposal for ATGC, a Delaware company, to acquire all issued shares, making Anteris a wholly owned subsidiary and redomiciling to the US.
Shareholders to receive one ATGC CDI or share per Anteris share, depending on election.
Timetable for court approval and implementation provided, with trading suspension expected upon effectiveness.
Latest events from Anteris Technologies
- Q2 2026 featured global trial expansion, U.S. Medicare reimbursement, and strong cash growth.AVR
Q2 2026 TU - Pre-commercial heart device company targets U.S. IPO to fund pivotal trials amid high growth potential and risk.AVR
Registration filing - Raising $90.6M to fund heart valve trials, but faces ongoing losses and high risk.AVR
Registration filing - Stockholders to vote on ASX waiver for new securities issuances and possible meeting adjournment.AVR
Proxy filing - 2024 net loss rose to $76M, cash insufficient for 12 months, additional funding required.AVR
H2 2024 - US IPO, clinical milestones, and strong R&D focus marked a pivotal year.AVR
AGM 2025 - Operating losses widened as PARADIGM Trial preparations accelerated and cash fell to $28.4M.AVR
Q2 2025 TU - Option holders voted on a scheme to exchange their options for equivalent securities in ATGC.AVR
Option Scheme Meeting - Net loss rose 36% to $21.9M as R&D and trial costs surged, straining cash reserves.AVR
Q1 2025